Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 11;12:1811–1820. doi: 10.2147/DMSO.S217924

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Wang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Down-regulation of Calpain 10 protected podocytes and reduced cell apoptosis under hyperlipidemic condition. (A) Effect of PA on podocyte viability. Podocytes were cultured with PA at different concentrations (50, 100, 150 μM) for various times (24, 48, 72 h). Relative cell viability was assessed with CCK-8. (B) Calpain 10 expression was identified by Western blot analysis. (C) Calpain 10 mRNA expression was tested by Real-time PCR. (D) Relative cell viability in podocytes treated as indicated was assessed with CCK-8. (E, H) Podocyte apoptosis in Control, PA, PA+siCalpain 10 was examined with Tunel-positive staining (original magnification×400). (F) Calpain 10, nephrin and caspase-3 expression in podocytes was identified by Western blot analysis. (G) Immunofluorescent for Calpain 10 and nephrin in podocytes treated as indicated (original magnification×630). Values are the mean ± SD; n=5,**P<0.01 compared with the control group; ^ΔΔP<0.01 compared with the Calpain10-Con group; ^#P<0.05,^##P<0.01 compared with the PA+Calpian10-Con group.

Abbreviations: PA, palmitate; siCalpain 10, the podocytes transfected by the Calpain 10-specific siRNA; Calpian10-Con, the podocytes transfected by scrambled siRNA.